VADUZ, Liechtenstein, Sept. 8, 2026 /PRNewswire/ -- Implantica AG (publ.) reminds investors and media that it will host its Capital Markets Day on September 9, 2026, from 14:00-16:30 CEST in Stockholm. The event will focus on Implantica's plans following the recent FDA approval of RefluxStop®, including the company's strategy for the U.S. market launch and the significant growth opportunity ahead, in a market where an estimated 78 million people in the U.S. suffer from acid reflux.

The Capital Markets Day will bring together Implantica's management team, RefluxStop® surgeons, and patients to provide investors with insights into RefluxStop®, including clinical and patient perspectives, while management will present the company's U.S. rollout strategy and the road ahead.

When:

September 9, 2026, 14:00-16:30 CEST

Location:

Sergelkonferensen, Mäster Samuelsgatan 42, Stockholm -- Wall Street conference room

Registration:
investorrelations@implantica.com

For those unable to attend in person, the event will be available via live webcast.

Click here to join the webcast: https://www.youtube.com/live/4lO08kiMX2I

For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)43 505 20 57
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on September 8, 2026, at 8:00 a.m. CEST.

About Implantica

Implantica is a medtech company focused on bringing advanced implantable technologies into the body designed to improve patient outcomes and quality of life. The company's lead product, RefluxStop®, is an FDA approved and CE-marked implant for the treatment of gastroesophageal reflux disease (GERD) with the potential to transform the standard of care in anti-reflux surgery, supported by strong long-term clinical outcomes.

In addition to RefluxStop®, Implantica has developed a broad, patent-protected product pipeline partly incorporating two platform technologies: an eHealth platform designed to enable communication with and remote monitoring and control of implants inside the body, and a wireless energizing platform designed to wirelessly power implantable devices through intact skin. These investigational devices are intended to facilitate remote changes to treatment, potentially saving cost for society.

Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

About RefluxStop®

RefluxStop® is a treatment for GERD designed to address the root cause of acid reflux. Conventional anti-reflux surgical procedures typically rely on encircling the esophagus and are often associated with side effects such as swallowing difficulties, inability to belch or vomit, and gas bloating. RefluxStop is different and aims to restore and maintain the lower esophageal sphincter in its natural anatomical position without encircling or applying pressure on the food passageway. Commercial performance from a multitude of centers supports the clinical study data collected and shows that the RefluxStop® device can successfully treat GERD without wrapping or constricting the esophageal sphincter, thereby avoiding the side effects commonly seen with the other current treatment approaches. Long-term 5-year clinical outcomes on RefluxStop® have been published in peer-reviewed scientific journals and support that a significant portion of the patient population will achieve clinically meaningful results, with minimal risks, when used in accordance with the indications for use.

Indications for Use: RefluxStop® is an implantable sterile medical device intended to treat acid and non-acid reflux in patients diagnosed with gastroesophageal reflux disease (GERD). The device ensures maintenance of a normal physiological situation for the gastroesophageal junction (GEJ) in a defined intra-abdominal position, allowing natural physiological function of the lower esophageal sphincter (LES), thereby reducing or eliminating acid and non-acid reflux. The RefluxStop® Deployment Tool is indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD), defined by abnormal impedance pH and/or pH testing, and indicated for RefluxStop® implantation.

Community
https://ch.linkedin.com/company/implantica
https://www.twitter.com/implantica

Media Contact:
Implantica AG
Juanita Eberhart, VP Marketing & Advocacy
juanita.eberhart@implantica.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/implantica/r/implantica-to-host-capital-markets-day-in-stockholm-on-september-9,c4393043

The following files are available for download:


 
 https://mb.cision.com/Main/19732/4393043/4256051.pdf                 Implantica to host Capital Markets Day in Stockholm on
                                                                          September 9



 
 https://news.cision.com/implantica/i/logo-transparent-1-8,c3562823 
 logo transparent 1 8

View original content:https://www.prnewswire.co.uk/news-releases/implantica-to-host-capital-markets-day-in-stockholm-on-september-9-302871976.html

Tags

More Like This

Implantica to host Capital Markets Day in Stockholm on September 9

Implantica's Capital Markets Day webcast available on demand

Implantica takes a big step forward at its 2nd Annual RefluxStop™ Users Meeting

Implantica publishes Interim Report January - March 2026 (Q1)

Implantica publishes Year-end Report, January - December 2023 (Q4)

Implantica publishes Annual Report 2024

Implantica announces highly successful 2024 American Foregut Society meeting where RefluxStop® received remarkable pre-launch market feedback

Implantica ramps-up production with 10,000 RefluxStop® units in preparation for U.S. launch, pending FDA PMA approval